A2B Adenosine Receptor as a novel target in cancer immunotherapyvalidation and optimization of new ligands

  1. Prieto Díaz, Rubén
Dirixida por:
  1. Eddy Sotelo Pérez Director

Universidade de defensa: Universidade de Santiago de Compostela

Fecha de defensa: 06 de outubro de 2023

Tribunal:
  1. Santiago Vázquez Cruz Presidente/a
  2. Julio César Castro Palomino Laria Secretario/a
  3. María Laura Bolognesi Vogal
Departamento:
  1. Departamento de Química Orgánica

Tipo: Tese

Resumo

This doctoral thesis focuses on the study of purinergic signaling in cancer, specifically targeting adenosine receptors. The main objective is the development of potent and selective nonxanthine- based antagonists for adenosine A2B receptors, with potential applications in cancer-targeted therapies. Molecular design strategies, synthesis, biological evaluation, structureactivity relationships, enantiospecific recognition and molecular modeling are explored. To the end, a rational method for dual A2A/A2B antagonists were obtained. The optimization and preclinical validation of new ligands for cancer (immuno)therapy are investigated, revealing promising data in terms of pharmacokinetics and pharmacodynamics.